Featured Articles

Roche announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (US) with…
Read More...

GSK plc and CureVac N.V. announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their…
Read More...

The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD)…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology…
Read More...

Novo Nordisk announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the…
Read More...

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo and…
Read More...

Eli Lilly and Company announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.…
Read More...

AstraZeneca’s Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the US as treatment for adult patients with…
Read More...

Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and…
Read More...

Charles River Laboratories International, Inc. and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany,  announced a plasmid DNA and retrovirus vector…
Read More...

AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in…
Read More...

AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D)…
Read More...

GSK plc announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics,…
Read More...

QIAGEN announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several…
Read More...

Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of PREZCOBIX…
Read More...

AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational, oral…
Read More...

Merck, known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, announced that the companies…
Read More...

Merck, a leading science and technology company, has launched its M-Trace Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing. The software…
Read More...

Johnson & Johnson announced it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and…
Read More...